Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
225.54
-0.86 (-0.38%)
Streaming Delayed Price
Updated: 10:58 AM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
Today 10:20 EDT
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
July 19, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 19, 2024
From
The Schall Law Firm
Via
Business Wire
Key Takeaways From Biogen Analyst Ratings
July 12, 2024
Via
Benzinga
Will BIOGEN INC breakout?
July 11, 2024
Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?
Via
Chartmill
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
July 18, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 16, 2024
From
Schall Law
Via
GlobeNewswire
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.
July 15, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
July 15, 2024
Revenue is climbing at these two drug companies -- and the trend should continue.
Via
The Motley Fool
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
July 12, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
July 11, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
BIIB Investors Have Opportunity to Join Biogen Inc. Securities Fraud Investigation with the Schall Law Firm
July 11, 2024
From
The Schall Law Firm
Via
Business Wire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 09, 2024
From
Schall Law
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
July 08, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
July 04, 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP
July 02, 2024
From
Robbins LLP
Via
GlobeNewswire
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 02, 2024
From
Schall Law
Via
GlobeNewswire
Biogen Completes Acquisition of Human Immunology Biosciences
July 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
July 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
July 01, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
This Is Massive News for Eli Lilly Investors
June 29, 2024
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
Via
The Motley Fool
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
June 28, 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
June 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
June 27, 2024
China is the Third Country to Launch LEQEMBI Following the United States and Japan
From
Biogen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.